Compare ARK Genomic Revolution ETF (ARKG) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.75. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ARKG | YMAG | |
|---|---|---|
Sector | Sector/Thematic | Income / Options Overlay |
52-Week High | $43.57 | $15.98 |
52-Week Low | $23.09 | $11.00 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
YMAG trades at $11.81 with a 1.2% daily gain, showing modest momentum amid bearish technical signals. The ETF's weekly dividend strategy provides income but faces headwinds from its overall bearish technical rating and mixed oscillators. Recent news highlights YieldMax's consistent distribution announcements, though analyst coverage remains limited for this specialized fund-of-ETFs product.
The outlook remains cautious given the bearish technical setup and structural concerns about NAV decay in option-income strategies. While weekly distributions offer income appeal, the fund's performance depends heavily on volatility monetization capabilities during rangebound markets. Key risks include expense ratio drag and underperformance during strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
